Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on VERONA PHARMA PLC. We currently have 67 research reports from 4 professional analysts.
|27Feb17 07:00||RNS||Final Results|
|23Feb17 07:00||RNS||Notice of Results|
|22Feb17 07:00||RNS||First COPD patient dosed with RPL554|
|13Feb17 07:00||RNS||Total Voting Rights & Block Listing Interim Review|
|08Feb17 13:31||RNS||Result of General Meeting and Share Consolidation|
|18Jan17 07:00||RNS||Publication of Circular|
|11Jan17 07:00||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
VERONA PHARMA PLC
VERONA PHARMA PLC
N+1 Singer - Verona Pharma - Full year results highlight a busy year
27 Feb 17
Verona Pharma’s 2016 full year results highlight a busy year for the group. Positive data from the group’s lead compound, RPL554, was reported and a £44.7m equity capital raise undertaken. 2017 looks set to be another busy year for the group with a Phase IIa trial already commenced (evaluating RPL554 as an add-on to tiotropium). We expect Verona Pharma to also commence a Phase I PK trial in maintenance COPD, a Phase IIa trial in cystic fibrosis and a Phase IIb dose-ranging trial in COPD in 2017 as well as undertake a NASDAQ listing. We remain upbeat and look forward to the development updates during the year.
N+1 Singer - Verona Pharma - Phase IIa RPL554 add-on trial to tiotropium commenced
22 Feb 17
The commencement of the Phase IIa trial evaluating RPL554 as an add-on therapy to tiotropium is encouraging and in line with expectations. Top line data is expected in Q4 2017. In 2017 we also expect the group to commence and report top line data from a Phase IIa trial in Cystic Fibrosis, to commence a Phase IIb 4-week dose-ranging trial in COPD and undertake a NASDAQ listing. We remain upbeat about Verona Pharma’s future prospects and look forward to its development updates during the year.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Verona Pharma - Publication of circular and proposed share consolidation
18 Jan 17
Verona Pharma announced a £44.7m equity capital raise in June 2016 in order to progress RPL554 through Phase IIb trials. At the same time the group announced its intentions to pursue a listing of ADSs as part of an IPO in the US on NASDAQ. The group has this morning announced the publication of its circular and a proposed share consolidation (50 to 1) to achieve an appropriate listing price. Verona Pharma is at an exciting stage of its development with its proprietary suspension formulation of its first-in-class RPL554. The group has reported positive data from all its Phase IIa trials with the new nebulised formulation of RPL554. 2017 looks set to be a busy year for the group as we expect it to commence and report top line data from a Phase IIa trial in Cystic Fibrosis, to commence a Phase IIb trial in COPD and undertake a NASDAQ listing. If development goes according to plan, RPL554 could be in a position to commence Phase III trials by the end of 2018.
N+1 Singer - Verona Pharma - 2017: NASDAQ listing and Ph IIa Cystic Fibrosis data
05 Jan 17
Verona Pharma is at an exciting stage of its development with a new proprietary suspension formulation of its first-in-class RPL554. The group has reported positive data from all its Phase IIa trials with the new nebulised formulation of RPL554. In 2017 we expect the group to commence and report top line data from a Phase IIa trial in Cystic Fibrosis, to commence a Phase IIb trial in COPD and undertake a NASDAQ listing. If development goes according to plan, RL554 could be in a position to commence Phase III trials by the end of 2018.
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
£21m equity raise to accelerate growth
22 Feb 17
Blindly following what others do is often a recipe for disaster. However, when an army of ‘super smart’ fund managers snap-up a big holding in a rapidly expanding small-cap that owns ‘disruptive’ technology addressing multi-$billion markets, then it is usually worth taking note. This is exactly what has happened at Kromek, a next generation radiation detection firm. Having just successfully completed its oversubscribed £20m placing and £1m open offer at 20p/share - supported by esteemed investors such as Gervais Williams at Miton (largest shareholder at 19.0%) and Katie Potts (Herald 5.35%), as well as several others such as Schroders (5.0%) and Killik (4.1%).
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume